Day One Director Saira Ramasastry Exits All Equity in $21.50 Servier Cash Merger

TL;DR: Director Saira Ramasastry cashed out all her Day One Biopharmaceuticals equity in the Servier merger, receiving $21.50 for each share and equivalent value for her RSUs and options. After the April 23, 2026 closing, she holds no remaining shares or awards.

The merger agreement required that all outstanding equity—common shares, restricted stock units and stock options—be canceled and paid in cash at the closing date. Unvested awards were accelerated to vest immediately before the effective time. The transaction closed on April 23, 2026, after regulatory approvals.

As a result, every holder of Day One equity received cash based on the offer price, adjusted for any option exercise costs and withholding taxes. The mechanism ensures that equity holders exit the company with liquid consideration rather than retaining stock in the combined entity.

Each of those securities was exchanged for a cash payment equal to $21.50 per underlying share, less the option’s exercise price where applicable and any required tax withholdings. The filing does not list a gross dollar amount because the net cash varies per award.

After these disposals, the derivative section of the filing lists zero remaining options and the equity section shows no shares or RSUs for Ramasastry. Her holdings in Day One are now completely cash‑settled.

Because the transactions are recorded as dispositions to the issuer, they primarily document the mechanical conversion required by the merger agreement. They do not signal a personal decision to sell or buy shares in the open market.

For investors, the filing confirms that the director’s financial stake in Day One has been fully liquidated, aligning her post‑merger interests with the cash proceeds rather than any ongoing equity in the combined business.